Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.
1 other identifier
observational
10
1 country
1
Brief Summary
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. The investigators plan to measure these factors prior to and after bronchoscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2009
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2009
CompletedFirst Submitted
Initial submission to the registry
June 24, 2009
CompletedFirst Posted
Study publicly available on registry
June 29, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2011
CompletedApril 9, 2012
April 1, 2012
1 year
June 24, 2009
April 5, 2012
Conditions
Keywords
Outcome Measures
Secondary Outcomes (1)
Volume of blood loss during the procedure
1 day
Study Arms (1)
Lung cancer
Comparison between individuals with and without pulmonary malignancy
Eligibility Criteria
Patients from the VAMC in Oklahoma city
You may qualify if:
- Any patient scheduled to undergo bronchoscopy
You may not qualify if:
- Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000
- Patients not scheduled to undergo bronchoalveolar lavage (BAL)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
VA Medical Center
Oklahoma City, Oklahoma, 73104, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jijo John, MD
University of Oklahoma
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 24, 2009
First Posted
June 29, 2009
Study Start
June 1, 2009
Primary Completion
June 1, 2010
Study Completion
October 1, 2011
Last Updated
April 9, 2012
Record last verified: 2012-04